Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Anal Biochem ; 334(2): 227-33, 2004 Nov 15.
Article in English | MEDLINE | ID: mdl-15494128

ABSTRACT

Lysosomal acid beta-glucocerebrosidase hydrolyzes glucocerebroside to glucose ceramide. Patients diagnosed with Gaucher disease, however, lack this enzyme, leading to the accumulation of glucocerebroside in tissue macrophages within multiple organs. Such patients can receive enzyme replacement therapy during which a human placental-derived or recombinant form of acid beta-glucocerebrosidase is targeted to the macrophages. As part of evaluating the effectiveness of such therapies, currently available methodologies for measuring acid beta-glucocerebrosidase activity are primarily conducted in cultured cell lines or tissue culture. However, these in vitro assays are limited by their ability to evaluate the efficacy of in vivo acid beta-glucocerebrosidase replacement therapy in animal models. In particular, there is an unmet need to simultaneously define cellular localization and evaluate enzyme activity following treatment in vivo. In addition, results of commonly used fluorescent-based assays for enzyme activity are difficult to compare day to day and/or across laboratories due to the variability inherent in flow cytometric measurement. In this article, we describe a reproducible and consistent quantitative method for the combined measurement of fluorescein intensity from enzyme-substrate conversion and cell localization by phenotype-specific phycoerythrin-antibody staining. Following infusion of recombinant human acid beta-glucocerebrosidase in mice, nonparenchymal cells are prepared from the livers of treated and control animals. Acid beta-glucocerebrosidase activity is measured in molecules of equivalent soluble fluorophore units within Kupffer cell populations as defined by phenotype-specific monoclonal antibodies. This assay should be applicable to investigations of other Gaucher disease treatments in both human and animal models.


Subject(s)
Flow Cytometry/methods , Glucosylceramidase/metabolism , Inositol/analogs & derivatives , Liver/cytology , Liver/enzymology , Lysosomes/enzymology , Animals , Cells, Cultured , Dose-Response Relationship, Drug , Female , Glucosylceramidase/administration & dosage , Inositol/administration & dosage , Mice , Mice, Inbred BALB C , Reproducibility of Results
2.
Curr Protoc Toxicol ; Chapter 6: Unit6.8, 2003.
Article in English | MEDLINE | ID: mdl-23045094

ABSTRACT

The involvement of reactive metabolites in cancer and cellular necrosis has been well established. The nucleophile, glutathione, provides a major mechanism of intracellular protection from electrophilic metabolites. Conjugation with glutathione to generate stable, water-soluble metabolites has been utilized to determine the nature and rates of formation of precursor reactive metabolites. In addition, because activities of the glutathione transferases may play a key role in tissue/cellular susceptibilities to electrophilic compounds, measurement of catalytic activities of these proteins can play an important role in discerning the underlying mechanisms of cell-selective toxicities. This unit outlines HPLC methods found to provide good separation of glutathione conjugates and includes two additional procedures that can be utilized in experiments where high throughput assays are needed for measuring transferase activities.


Subject(s)
Glutathione/chemistry , Animals , Chromatography, High Pressure Liquid , Cytosol/enzymology , Glutathione/analysis , Glutathione Transferase/metabolism , Mass Spectrometry , Mice , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Nuclear Magnetic Resonance, Biomolecular , Spectrophotometry, Ultraviolet
SELECTION OF CITATIONS
SEARCH DETAIL